Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.
BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures.
ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.
UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.
Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1million to £3 million, in order to capitalise on exciting investment opportunities and support its existing portfolio.
The Rosalind Franklin Laboratory, a state-of-the-art, fully fitted CL2 lab facility in Leamington Spa, Warwickshire, has come to market, with global real estate advisor, Avison Young, promoting it as an ‘unmissable opportunity’ for the UK life sciences sector.